The local government issued a new policy that the drug administration of 10 provinces (cities) was officially listed
The main leaders have appointed the Guangdong Drug Administration to be listed on October 19
The main leading members are Luo Wenzhi, Secretary of the Party group and director of the Guangdong Drug Administration
The Heilongjiang drug administration was listed on October 25
The main leading members are Li Jun, director of the Heilongjiang drug administration, Shanxi Province Listing time of SFDA: October 29, main leading members: Fang Yaming is secretary of the Party group and director of Shanxi drug administration Jilin drug administration listing time: October 22, main leading members: Liu Baofang is secretary of the Party group and director of Jilin drug administration Shandong drug administration listing time: October 26 Main leading members: guidunshan is the Secretary of the Party group of Shandong drug administration and the director of Jiangsu drug administration
Listing time: October 26
Main leading members: Wang Yue is the Secretary of the Party group of Jiangsu drug administration
Listing time: October 26
Main leading members: Zhou Longhai is the Secretary of the Party group of Chongqing drug administration and the director of Zhejiang Province Listing time of Drug Administration: October 26, main leading member: Xu Runlong: Secretary of Party group and director of drug administration of Zhejiang Province; listing time of Hebei Drug Administration: November 3, main leading member: Xu yanzeng: Secretary of Party group and director of drug administration of Hebei Province; listing time of Jiangxi drug Administration: November 3 Main leading members: Cao Qi is the Secretary of the Party group of Jiangxi drug administration, and Shangguan Xinchen is the director of Jiangxi drug administration
In addition, the listing of medical insurance bureaus in various provinces and cities has also been put on the agenda
It is reported that the reform plans of 19 provinces (regions, municipalities directly under the central government) have been approved and made public, including Hainan, Fujian, Shandong, Jiangxi, Hubei and other 19 provinces, among which the medical insurance bureaus are at the level of the main department: Guangdong, Jiangxi, Chongqing, Jilin, Shandong, Hainan, Liaoning, Sichuan, Heilongjiang, Fujian, Hubei, Jiangsu, Zhejiang and other 13 provinces; the medical insurance bureaus are at the level of the deputy department: Ningxia, Guangzhou There are 6 provinces in the west, Hunan, Shanxi, Hebei and Gansu
For the position of the leaders of the provincial health insurance bureau that has been unveiled, please read the article: 12 "top leaders" of local medicine have been determined! 23 provinces said the proportion of drugs not used in national negotiations! Thousands of hospital pharmacies cheat huge amount of medical insurance? 6 provinces (cities) issued documents to implement the new drug base catalogue
Since the release of the 2018 version of the drug base catalogue, all provinces and cities are also actively improving the requirements of the national basic drug system
It is reported that at present, Shandong, Inner Mongolia, Chongqing and Henan have issued documents, all of which stipulate the situation of supplementary drugs in their provinces (cities)
Shandong clearly requires that, from November 1, the original "supplementary drugs of Shandong Province" not included in the 685 national base directory will no longer retain the "basic drug attribute" of the provincial centralized procurement platform
Chongqing issued a document on October 31, which made it clear that the catalogue of 2018 version will be officially implemented from November 1, 2018, and the original catalogue of supplementary drugs of Chongqing Municipality for national essential drugs (2013 version) will be abolished from the same day
In addition, the city requires that after the publication of the new version of the national essential drug catalogue, in principle, there should be no more supplementary drugs
At the same time, Chongqing pharmaceutical exchange is also required to sort out the listing of drugs in the 2018 version of the directory, open a green channel, ensure that all the drugs in the directory should be listed, and unblock the procurement channel
On October 31, Henan Province issued a notice that after the publication of the new version of the national essential drug catalog, no additional drugs should be added in principle in all regions; in the 2018 version of the catalog, if there is a price limit for drugs on the Henan medicine procurement platform, the medical and health institutions shall not exceed the price limit for purchasing, while for those without the price limit, the medical and health institutions shall negotiate with the drug production or distribution enterprises for purchasing; and The proportion of basic drugs used in tertiary general hospitals is more than 30%, that in urban secondary general hospitals is more than 45%, and that in county (city) general hospitals is more than 50%
Special hospitals should give priority to basic drugs
On October 31, Inner Mongolia issued a notice to adjust the basic drug properties of some online varieties
The scope of adjustment is that the drugs on the Internet in Inner Mongolia belong to the adjustment part of the national basic drug catalog (2018 version), which will be implemented from November 1, 2018
In addition to the official documents issued by the above four regions, Tianjin and Hainan also successively issued corresponding policies
Tianjin requires that after the new version of the national essential drug catalog is published, in principle, no additional catalog will be developed
Hainan Province has revised the catalog types of relevant drugs in the centralized drug purchase platform according to the new version of the national essential drug catalog
Up to now, 17 kinds of anticancer drugs have been included in the medical insurance in 8 places, with a drop of up to 70%
According to incomplete statistics, there have been 8 places in China that have issued documents to include 17 kinds of anticancer drugs such as azacytidine into the local medical insurance reimbursement scope, and published the drug price and implementation date
Sichuan Province: key points of policy issued on October 22: 17 kinds of anti-cancer drugs, such as azacytidine, will be included in the category B scope of the catalogue of drugs for basic medical insurance, work injury insurance and maternity insurance of Sichuan Province (2018 version), and will be managed according to the single payment guarantee mode of drugs
Drug price: the average decrease rate is 56.7%
Implementation date: November 1, Zhejiang Province: October 12, key points of the policy: 17 kinds of anti-cancer drugs, such as azacytidine, were included in the scope of medical insurance B in Zhejiang Province
The payment standard, limited payment scope and drug classification code of medical insurance were implemented according to the national regulations
Drug price: the average drop is 56.7%
Implementation date: November 1 Ningxia Autonomous Region: October 23 key points of policy: all 17 kinds of anticancer drugs, such as azacytidine, will be included in the scope of medical insurance B in Ningxia Autonomous Region, and drugs marked with the limited payment scope will be implemented in accordance with the relevant provisions of the limited payment management of medical insurance
Drug price: an average decrease of 56.7%
Implementation date: November 30, Guangdong Province: key points of policy issued on October 28: all 17 kinds of anti-cancer drugs, such as azacytidine, are included in the reimbursement scope of medical insurance in Guangdong Province; national negotiated drug purchase and use are taken as the assessment indicators of agreement management of designated medical institutions, and are linked with the pre allocation of medical insurance funds; and drug supply channels are widened
Drug price: an average decrease of 56.7%
Implementation date: November 30, Beijing: October 31, key points of policy: all 17 kinds of anticancer drugs, such as azacytidine, will be included in the reimbursement scope of Beijing medical insurance, and at the same time, the above drugs will be included in the reimbursement scope of outpatient special diseases
Drug price: drop up to 70% implementation date: November 15 Hunan Province: October 30 key points of policy: all 17 kinds of anticancer drugs, such as azacytidine, will be included in the reimbursement scope of Beijing medical insurance, at the same time, the above drugs will be included in the reimbursement scope of outpatient special diseases, and also be included in the management scope of special drugs for medical insurance in the whole province
Drug price: an average decrease of 56.7%
Implementation date: from November in Gansu Province: key points of policy issued on October 29: 17 kinds of anticancer drugs, such as azacytidine, will be included in the category B scope of basic medical insurance, work-related injury insurance and maternity insurance for urban employees
Implementation date: Nov
18 Fujian Province: Oct
11 key points of policy: 17 national negotiated drugs will be included in the category B scope of Fujian medical insurance drug catalog
Drug price: according to the limited payment scope stipulated by the state, the implementation date is October 25
At the same time, 14 provinces (cities) in Hubei, Sichuan, Guangzhou, Tianjin, Fujian, Heilongjiang, Zhejiang, Beijing, Chongqing, Yunnan, Inner Mongolia, Ningxia, Liaoning and Shandong have issued documents to implement the procurement of negotiated drugs in this year
The first flow transfer prescription came out, and the out of hospital market ushered in the "profit outlet" on October 25
Guangdong Second People '
It is reported that the hospital will issue more than 6000 prescriptions every day, of which about half will be self paid prescriptions, that is, about 3000 prescriptions will enter the prescription circulation platform every day
According to the average 200 yuan per prescription, it is estimated that the second hospital of Guangdong Province alone will bring more than 200 million yuan of prescription drug sales volume to retail pharmacies in one year
Some people in the industry believe that this policy is conducive to further breaking down the "drug based medicine", and is expected to solve the deep-seated problems in the drug circulation link, which is of great significance to medical reform
The suspension of the examination for pharmacists at the beginning and intermediate level in Guangdong triggered speculation among the industry
On November 1, Guangdong personnel examination website released the notice on suspension of the examination for the qualification of pharmacists at the beginning and intermediate level in Guangdong Province
It is pointed out in the document that, according to the spirit of superior documents, due to the adjustment of charge management mode for the preliminary and intermediate professional technical qualification examination of pharmacy, the preliminary and intermediate professional technical qualification examination of pharmacy in Guangdong Province is suspended, and relevant matters will be notified after further investigation and demonstration
However, from the analysis of the affiliation agreement of pharmacist certificate, the new version of GSP and 140 national vocational qualification catalogues officially published in 2017, some industry figures speculated that the provincial pharmaceutical professional and technical qualification examination might be cancelled
Four dynamic enterprises of local pharmaceutical enterprises have obtained the reward funds for passing the consistency evaluation of generic drugs, totaling 6 million yuan according to incomplete statistics
At present, four enterprises have obtained the reward funds for passing the consistency evaluation of generic drugs
On October 22, montmorillonite powder of Sichuan Weiao Pharmaceutical Co., Ltd
obtained 1.5 million yuan of consistency evaluation award from Sichuan food and Drug Administration for the consistency evaluation of quality and efficacy of generic drugs; on September 4, pemetrexed disodium for injection of Sichuan Huiyu Pharmaceutical Co., Ltd
obtained 1.5 million yuan of consistency evaluation from Sichuan food and Drug Administration for the consistency evaluation of quality and efficacy of generic drugs Reward fund: on May 4, Sichuan Kelun's escitalopram oxalate tablets obtained RMB 1.5 million from Sichuan food and Drug Administration for consistency evaluation of quality and efficacy of generic drugs; on March 20, Chengdu Beite pharmaceutical's tenofovir dipivoxil fumarate tablets obtained from Sichuan food and Drug Administration for consistency evaluation of quality and efficacy of generic drugs 1.5 million yuan of consistency evaluation Award Fund
*St Changsheng has been suspended for more than two months, and now its total market value is 3.011 billion yuan
According to the relevant provisions of the Listing Rules of Shenzhen Stock Exchange, because * ST Changsheng cannot disclose the regular report within two months after the suspension of trading from September 3, 2018, the trading of shares will resume from November 5, 2018
However, after resumption of trading, * ST Changsheng's share price was 3.1 yuan / share, down 4.91% compared with 3.26 yuan / share before suspension of trading, corresponding to a total market value of 3.011 billion yuan
In addition, within two months after wearing the hat "* ST", if * ST Changsheng still fails to disclose the regular report, then * ST Changsheng's shares may be terminated by Shenzhen Stock Exchange
Within two months after the termination of the transaction, * ST Changsheng is still unable to disclose the semi annual report, and the company may be terminated from listing
Huahai Pharmaceutical Co., Ltd
issued a notice on November 5, saying that the company's anda (American generic drug application) was approved for listing
According to the announcement, Gelong ammonium bromide injection was developed by West ward pharmaceuticals and was listed in the United States in 1982
The main manufacturers of glulammonium bromide injection in the U.S
region are hikma, American regent, etc., and the revenue in 2017 was about 180 million U.S
dollars (limited to the U.S
region), but there is no such product on the market in China
In addition, Huahai pharmaceutical has invested about 11.3 million yuan in the research and development of Gelong ammonium bromide injection project
Information source: yaozhi.com, pharmaceutical cloud studio, bureau of health and knowledge, cypress blue, hexun.com and other statements: This paper only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please
